Elucidating the Molecular Mechanisms of Vitex negundo L. in Polycystic Ovary Syndrome via Metabolomics‐Driven Network Pharmacology
Biomedical Chromatography · 2026-09 · 40 (9)
DOI: 10.1002/bmc.70592 ↗At a glance
Journal article in Biomedical Chromatography, published online on 2026-08-10. Written by Nishmitha R Poojary and 4 co-authors. Institution: Department of Biotechnology, Manipal School of Life Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India. Major MEDLINE topics: Vitex, Metabolomics, Polycystic Ovary Syndrome, Metabolome. 28 references. The full text is freely available (open access, CC BY 4.0). Funded by: Manipal Academy of Higher Education, Manipal, India, Manipal Academy of Higher Education.
Abstract (original language)
Polycystic ovary syndrome (PCOS) is a hormonal disorder marked by irregular menstrual cycles, elevated androgen levels, ovarian cysts, hirsutism, acne and other symptoms. While conventional medications such as Metformin and Spironolactone are commonly prescribed, they are often associated with undesirable side effects. As a result, there is growing interest in alternative treatments, particularly those involving medicinal plants. Vitex negundo L., a member of the Lamiaceae family, has demonstrated promising therapeutic effects against PCOS. However, its precise molecular mechanism of action remains unclear. To explore this, we conducted an untargeted metabolomics analysis using UPLC‐MS/MS to identify bioactive compounds, followed by network pharmacology to elucidate potential mechanisms. Metabolite fingerprinting revealed 186 metabolites, among which 122 were identified as secondary metabolites. Network pharmacology analysis uncovered 910 potential targets associated with the identified compounds and 297 known PCOS‐related disease targets, with 50 overlapping targets between the two datasets. Key hub targets identified included P53, ESR1, AKT1, STAT3, CTNNB1, ERBB2, BCL2, EGFR, MTOR and IL6. Furthermore, molecular docking highlighted several bioactive constituents—syringin, 4‐(3,4‐dihydroxyphenyl)‐6,7‐dihydroxynaphthalene‐2‐carboxylic acid, and Isovitexin—as potential lead compounds for PCOS treatment. Further evaluation of lead compounds can be conducted through in vitro and in vivo studies.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Biotechnology, Manipal School of Life Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India.
ORCID profiles: Padmalatha S Rai
Funding
- Manipal Academy of Higher Education, Manipal, India
- Manipal Academy of Higher Education
Cite
APA
Poojary, N. R., Venkatasai, N. N., Sanjay, K. U., Kodanch, S. M., & Rai, P. S. (2026). Elucidating the Molecular Mechanisms of Vitex negundo L. in Polycystic Ovary Syndrome via Metabolomics‐Driven Network Pharmacology. Biomedical Chromatography, 40(9). https://doi.org/10.1002/bmc.70592
Vancouver
Poojary NR, Venkatasai NN, Sanjay KU, Kodanch SM, Rai PS. Elucidating the Molecular Mechanisms of Vitex negundo L. in Polycystic Ovary Syndrome via Metabolomics‐Driven Network Pharmacology. Biomedical Chromatography. 2026;40(9). doi:10.1002/bmc.70592
BibTeX
@article{Poojary2026,
author = {Poojary, Nishmitha R and Venkatasai, Neeharika Narisepalli and Sanjay, Kannath U and Kodanch, Supraja M and Rai, Padmalatha S},
title = {Elucidating the Molecular Mechanisms of Vitex negundo L. in Polycystic Ovary Syndrome via Metabolomics‐Driven Network Pharmacology},
journal = {Biomedical Chromatography},
year = {2026},
volume = {40},
number = {9},
doi = {10.1002/bmc.70592}
}
EUVIMED